Patients’ main characteristics and general technical strategy of study.

Number of included patients, methods of HIV sequencing and HLA typing are described for each participating center. MHC IC50 was predicted with TutuGenetics tool.本研究针对各参与中心，分别详述了其纳入的患者人数、人类免疫缺陷病毒（HIV）测序及人类白细胞抗原（HLA）分型的实验方案。主要组织相容性复合体（MHC）的半数抑制浓度（IC50）通过TutuGenetics工具进行预测。